ANTH - Anthera Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Anthera Pharmaceuticals, Inc.

The Pennzoil Building
Suite 1300 North Tower 700 Milam
Houston, TX 77002
United States
410-350-1839
http://www.anthera.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul F. TruexExec. Chairman100kN/A1969
Mr. John Craig ThompsonCEO & Director715.3kN/A1967
Ms. May LiuSr. VP of Fin. & Admin. and Principal Accounting OfficerN/AN/A1976
Dr. Paul Adams Ph.D.Sr. VP of Global Regulatory Affairs and ComplianceN/AN/A1963
Joshua CaldwellChief Liquidating Officer & DirectorN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Corporate Governance

Anthera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.